NexImmune Inc. (NASDAQ: NEXI) stock jumped 7.85% on Friday to $0.64 against a previous-day closing price of $0.60. With 1.08 million shares changed hands, the volume of the stock remained lighter than its average volume of 1.71 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $0.6899 whereas the lowest price it dropped to was $0.5800. The 52-week range on NEXI shows that it touched its highest point at $17.56 and its lowest point at $0.57 during that stretch. It currently has a 1-year price target of $3.50.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of NEXI was down-trending over the past week, with a drop of -18.23%, but this was down by -44.19% over a month. Three-month performance dropped to -70.69% while six-month performance fell -75.69%. The stock lost -96.12% in the past year, while it has lost -86.08% so far this year. A look at the trailing 12-month EPS for NEXI yields -2.68 with Next year EPS estimates of -1.16. For the next quarter, that number is -0.69. This implies an EPS growth rate of -65.20% for this year and 46.30% for next year.
Float and Shares Shorts:
At present, 22.87 million NEXI shares are outstanding with a float of 16.14 million shares on hand for trading. On Jul 14, 2022, short shares totaled 0.46 million, which was 1.99% higher than short shares on Jun 14, 2022. In addition to Ms. Kristi Jones R.Ph. as the firm’s CEO, Pres & Director, Mr. John Trainer M.B.A. serves as its Chief Financial Officer.
Through their ownership of 42.06% of NEXI’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 5.00% of NEXI, in contrast to 28.85% held by mutual funds. Shares owned by individuals account for 20.94%. As the largest shareholder in NEXI with 5.49% of the stake, ArrowMark Colorado Holdings LLC holds 1,326,043 shares worth 1,326,043. A second-largest stockholder of NEXI, Invus Public Equities Advisors LL, holds 1,200,000 shares, controlling over 4.97% of the firm’s shares. Slate Path Capital LP is the third largest shareholder in NEXI, holding 925,000 shares or 3.83% stake. With a 2.17% stake in NEXI, the Fidelity Select Port. – Biotechno is the largest stakeholder. A total of 525,000 shares are owned by the mutual fund manager. The Vanguard Total Stock Market Index, which owns about 1.31% of NEXI stock, is the second-largest Mutual Fund holder. It holds 315,228 shares valued at 0.37 million. Vanguard Extended Market Index Fu holds 0.40% of the stake in NEXI, owning 97,320 shares worth 0.11 million.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for NEXI since 4 analysts follow the stock currently. There are 2 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 2 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With NEXI analysts setting a high price target of $5.00 and a low target of $2.00, the average target price over the next 12 months is $3.50. Based on these targets, NEXI could surge 681.25% to reach the target high and rise by 212.5% to reach the target low. Reaching the average price target will result in a growth of 446.88% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. NEXI will report FY 2022 earnings on 03/29/2023. Analysts have provided yearly estimates in a range of -$1.55 being high and -$2.74 being low. For NEXI, this leads to a yearly average estimate of -$2.17. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. NexImmune Inc. surprised analysts by -$0.01 when it reported -$0.69 EPS against a consensus estimate of -$0.68. The surprise factor in the prior quarter was $0.04. Based on analyst estimates, the high estimate for the next quarter is -$0.66 and the low estimate is -$0.72. The average estimate for the next quarter is thus -$0.70.
Summary of Insider Activity:
Insiders traded NEXI stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has increased to 13 while that of sell transactions has remained unmoved to 0 over the past year. The total number of shares bought during that period was 468,257 while 0 shares were sold.